Model AER-501 - Inhaled Human Insulin for Type 1 and 2 Diabetes
We developed a soft mist inhaled human insulin for the treatment of Type 1 and 2 diabetes. Clinical data based on our five Phase 1/2a studies demonstrated AER-501 has: Faster onset and similar profile when compared to lispro. Intra and inter-subject variability similar to injections. Minimal to no cough following inhalation. These clinical studies also demonstrated the AFINA drop dispenser enables fast, accurate and precise dose loading at a low cost with low drop weight variability of 3-4%¹.
-
Most popular related searches
How It Works
Each administration event requires one to load the device only once, using 1–5 drops (55 to 275 microliters) allowing for fast administrations. The drop dispenser offers a strong, sterile microbial barrier to reduce contamination of the drug before administration while maintaining the stability of the formulations for long periods of time.
Partnership Opportunities
We plan to have an end-of-Phase 2 meeting with the FDA and then seek a partner to progress AER-501 into registration studies.
Precision Inhaled Drug Delivery
We are leveraging our proprietary inhalation technology, the AFINA Inhaler, which combines novel drug aerosol formulations and cutting-edge technology, to advance our diverse pipeline of inhaled therapies to treat cardiopulmonary and cardiometabolic conditions.
Customer reviews
No reviews were found for Model AER-501 - Inhaled Human Insulin for Type 1 and 2 Diabetes. Be the first to review!